
- /
- Supported exchanges
- / US
- / VXRT.NASDAQ
Vaxart Inc (VXRT NASDAQ) stock market data APIs
Vaxart Inc Financial Data Overview
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Vaxart Inc data using free add-ons & libraries
Get Vaxart Inc Fundamental Data
Vaxart Inc Fundamental data includes:
- Net Revenue: 47 395 K
- EBITDA: -48 238 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vaxart Inc News

Vaxart to be suspended from Nasdaq, plans to appeal delisting decision
Vaxart, Inc. (NASDAQ:VXRT), currently trading at $0.46 with a market capitalization of approximately $105 million, announced Tuesday it received a notice from the Nasdaq Stock Market stating that its ...


Vicarious Surgical adds two new directors to board
WALTHAM, Mass. - Surgical robotics company Vicarious Surgical Inc. (NYSE:RBOT), currently valued at $1.59 billion and showing strong momentum with a 27.61% gain last week, announced Monday the electio...

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (Vaxart or the Company), a clinical-stage biotechnology company developing a range of oral recombinant pill...

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral reco...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.